Assessment of costs associated with adverse events in patients with cancer

New Frameworks to Assess Value of Cancer Care: Strengths and Limitations

(2016) Lowell E. Schnipper et al.   ONCOLOGIST

The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States

(2016) Dominick Latremouille-Viau et al.   JOURNAL OF MEDICAL ECONOMICS

Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries

(2016) Katja Vouk et al.   JOURNAL OF MEDICAL ECONOMICS

American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options

(2015) Lowell E. Schnipper et al.   JOURNAL OF CLINICAL ONCOLOGY

Economic Burden Associated with Adverse Events in Patients with Metastatic Melanoma

(2015) Bhakti Arondekar et al.   Journal of Managed Care & Specialty Pharmacy

Clinical Impact of Chemotherapy-Related Adverse Events in Patients with Metastatic Breast Cancer in an Integrated Health Care System

(2015) Nazia Rashid et al.   Journal of Managed Care & Specialty Pharmacy

The Impact of Outpatient Chemotherapy-Related Adverse Events on the Quality of Life of Breast Cancer Patients

(2015) Tomoya Tachi et al.   PLoS One

Investigation of Adverse-Event-Related Costs for Patients With Metastatic Breast Cancer in a Real-World Setting

(2014) S. Hurvitz et al.   ONCOLOGIST

Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens

(2014) Ryan N Hansen et al.   SpringerPlus

Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force

(2013) Sean D. Sullivan et al.   VALUE IN HEALTH

Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin’s lymphoma in European and Australian clinical practice

(2012) Derek Weycker et al.   BMC CANCER

Adverse drug events resulting in admission to the intensive care unit in oncology patients: Incidence, characteristics and associated cost

(2012) Lama H Nazer et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Economic Burden of Dermatologic Adverse Events Induced by Molecularly Targeted Cancer Agents

(2011) Judy H. Borovicka   ARCHIVES OF DERMATOLOGY

Projections of the Cost of Cancer Care in the United States: 2010-2020

(2011) A. B. Mariotto et al.   JNCI-Journal of the National Cancer Institute

Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain

(2011) Kurt Banz et al.   LUNG CANCER

Microcosting Quantity Data Collection Methods

(2009) Kevin D. Frick   MEDICAL CARE

Assigning Resources to Health Care Use for Health Services Research

(2009) Paul A. Fishman et al.   MEDICAL CARE

The impact of using different costing methods on the results of an economic evaluation of cardiac care: microcosting vs gross-costing approaches

(2008) Fiona M. Clement (Nee Shrive) et al.   HEALTH ECONOMICS